Diadema Partners’s ALX Oncology ALXO Stock Holding History

Diadema Partners’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-197,680	Closed	-$330K	–	108
2024 Q4	$330K	Buy	+197,680	New	+$304K	0.14%	80

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diadema Partners's ALXO Position: Q1 2025 in Review

Diadema Partners sold out of ALX Oncology (ALXO) in Q1 2025, closing a stake of 197,680 shares — an estimated $330K sold.

Diadema Partners first reported a position in ALXO in Q4 2024 and held it in 1 quarter. The position peaked at $330K in Q4 2024. 85 funds tracked by Wall St. Rank hold ALXO as of Q1 2025.

Diadema Partners reported no remaining ALX Oncology position as of Q1 2025 after selling out during the quarter.
Diadema Partners sold 197,680 ALX Oncology shares in Q1 2025, an estimated $330K.
Diadema Partners first reported a position in ALX Oncology in Q4 2024 and held it in 1 quarter.
Diadema Partners's ALX Oncology position peaked at $330K in Q4 2024.
85 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.